Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9H1P3

UPID:
OSBL2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9H1P3; A8K736; Q6IBT0; Q9BZB1; Q9Y4B8

BACKGROUND:
The Oxysterol-binding protein-related protein 2 is integral to the cellular lipid transport mechanism, influencing cholesterol and phospholipid distribution within the cell. Its interaction with phosphatidylinositol-4,5-bisphosphate and various cholesterol forms demonstrates its critical role in maintaining lipid equilibrium, essential for cellular function and signaling.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Oxysterol-binding protein-related protein 2 could open doors to potential therapeutic strategies. Given its association with non-syndromic sensorineural hearing loss, exploring ORP2 as a therapeutic target offers promising prospects for developing novel treatments for this condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.